Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Hk Inno N Corporation operates in the Biotechnology & Pharmaceuticals technology area, where it currently has 7 pending office actions. These 7 pending office actions are distributed among 7 distinct examiners, indicating that each case is being handled by a different individual. This distribution suggests a diverse range of examiner interactions for the company's current portfolio.
The prosecution activity spans 5 distinct art units, which reflects the technical variety within the company's biotechnology and pharmaceutical innovations. HUTTER, GILLIAN A is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. This workload is a small part of the overall prosecution activity across the 5 distinct art units.
For practitioners, managing 7 distinct examiners requires a coordinated approach to ensure consistency in technical arguments. The involvement of multiple art units means that the company must navigate different sets of examination guidelines. Since HUTTER, GILLIAN A is responsible for only 1 busiest examiner pending office action, the prosecution tasks are widely dispersed across the available examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| OTTON, ALICIA L | 1 | 64.9% | +9.4% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| KOSTURKO, GEORGE W | 1 | 54.7% | +49.0% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282182 | NOVEL SALTS OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| 18032749 | ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND AND PREPARATION METHOD THEREOF | KASSA, TIGABU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19444750 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND | HUTTER, GILLIAN A | — |
| 18282182 | NOVEL SALTS OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| 18032749 | ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND AND PREPARATION METHOD THEREOF | KASSA, TIGABU | — |
| 17918386 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND | KOSTURKO, GEORGE W | — |
| 17802078 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1625 | 1 |
| 1699 | 1 |
| 1619 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19444750 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND | HUTTER, GILLIAN A | 1625 | §102§103DP | Non-Final OA | — | Pending | Jan 09, 2026 |
| 19444665 | NOVEL PREPARATION CONTAINING BENZIMIDAZOLE DERIVATIVE | OTTON, ALICIA L | 1699 | §102§103DPOther | Non-Final OA | — | Pending | Jan 09, 2026 |
| 18282182 | NOVEL SALTS OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18032749 | ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND AND PREPARATION METHOD THEREOF | KASSA, TIGABU | 1619 | §103§112 | Final Rejection | — | Pending | Apr 19, 2023 |
| 17918386 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND | KOSTURKO, GEORGE W | 1621 | §103 | Final Rejection | — | Pending | Mar 27, 2023 |
| 17802078 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | — | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial